The use of fremanezumab in children and adolescents with episodic migraine (EM) results in significant reductions in monthly migraine days (MMD) and monthly headache days (MHD), but it appears to be no better than placebo among those with chronic migraine (CM), as shown by outcomes from two randomized, phase III trials presented at AAN 2026.
